Bevifimod (Research-Grade) is a research-grade biosimilar monoclonal antibody targeting Immunoglobulin G-binding protein A. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: functional assays. Endotoxin: < 10 EU/mg. Purity: >95% as determined by SDS-PAGE. For research use only.
Immunoglobulin G-binding protein A is a ~55 kDa protein. Plays a role in the inhibition of the host innate and adaptive immune responses. Possesses five immunoglobulin-binding domains that capture both the fragment crystallizable region (Fc region) and the Fab region (part of Ig that identifies antigen) of immunoglobulins. In turn, Staphylococcus aureus is protected from phagocytic killing via inhibition of Ig Fc region. In addition, the host elicited B-cell response is prevented due to a decrease of antibody-secreting cell proliferation that enter the bone marrow, thereby decreasing long-term antibody production. Inhibits osteogenesis by preventing osteoblast proliferation and expression of alkaline phosphatase, type I collagen, osteopontin and osteocalcin.
Product Name:
Bevifimod (Research-Grade)
SKU:
GXBS02707
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
Immunoglobulin G-binding protein A
Applications:
Functional assay
Synonyms:
Immunoglobulin G-binding protein A, IgG-binding protein A, Staphylococcal protein A, SpA, spa
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
